Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants

Phase 1

Recruiting

• Conditions: Bronchopulmonary Dysplasia
• Interventions: Biological: Human Umbilical Cord Derived-Mesenchymal Stem Cells

• Registration Number: NCT03631420
• Lead Sponsor: Meridigen Biotech Co., Ltd.

Brief Summary

The clinical study with UMC119-01 is designed to investigate the safety in patients with bronchopulmonary dysplasia ("BPD"). This will be a dose escalation, open-label, single-center study in infants at high risk for BPD.

Detailed Description

UMC119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product which is intended for prevention of Bronchopulmonary dysplasia.

Study Timeline

• Study First Submitted: 2018-04-09
• Study First Submitted QC: 2018-08-13
• Study First Posted: 2018-08-15
• Study Start: 2018-10-26
• Status Verified: 2022-12
• Last Update Submitted: 2023-12-01
• Last Update Posted: 2023-12-04
• Primary Completion: 2025-12-31
• Study Completion: 2027-07-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

Neonatal infants who fulfil all of the following criteria will be enrolled:

1. Subjects of postnatal age between 3 to 30 days.
2. Are male and female infants born at GA between 23 weeks to 29 weeks. The postmenstrual age of subject received UMC119-01 should be no more than PMA36 weeks.
3. Subjects with birth weight between 501g to 1249 g.
4. Have endotracheal tube in place as part of SoC for preterm infants with BPD at screening and on treatment visit (Day 0), and that they will have not been intubated for the purposes of this study.
5. A subject who is intubated and receiving mechanical ventilation with a fraction of inspired oxygen (FiO2) of 0.25 or greater at Screening.
6. A subject who has had either a deterioration or no change in the setting of mechanical ventilation within the 24 hours before trial enrollment.
7. Written informed consent has been provided by the subject's parents, legal guardians, or a legal representative, who agree to comply with all of the study procedures, including those in the long-term safety surveillance period.

Exclusion Criteria

Neonatal infants who meet any of the following criteria will be excluded:

1. Have a major congenital abnormality, including neurological (including anencephaly and similar malformations), hepatic, renal, cardiovascular abnormality (except for patent ductus arteriosus, PDA).
2. Have a known genetic syndrome.
3. Have a condition that makes them ineligible for participation in this study, as determined by the investigator.
4. Have C-reactive protein (CRP) >30 mg/L; or any infections including pneumonia, sepsis, or shock.
5. Have pre-existing severe intraventricular hemorrhage (IVH) (grade ≥3).
6. Have active pulmonary hemorrhage or air leak syndrome.
7. Have abnormal hepatic (AST, ALT >150 U/L or direct bilirubin >2 mg/dL or total bilirubin >15 mg/dL) or renal function (serum creatinine >1 mg/dL or oliguria).
8. Are known to be infected with HIV or CMV.
9. Are expected to have surgery within 24 hours prior to and/or after UMC119 01 instillation.
10. Are expected to receive any other intratracheal treatments, including surfactant within 72 hours prior to and/or after UMC119 01 instillation.
11. Are currently participating in any other interventional clinical trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
UMC119-01	Human Umbilical Cord Derived-Mesenchymal Stem Cells	UMC119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product

Primary Outcome Measures

Name	Time	Method
The incidence and frequency of adverse events related to administration of UMC119-01.	3 months from the day of administration	• The incidence and frequency of adverse events (AEs) and serious adverse events (SAEs), including their relationship to the administration of UMC119 01.

Secondary Outcome Measures

Name	Time	Method
Changes of inflammatory markers (pg/ml) before and after administration.	3 days and 7 days after administration	Changes from baseline of inflammatory markers (pg/ml) .
Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA).	36 weeks postmenstrual age (PMA)	Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA).
The percentage of subjects who died from any cause during the study.	3 months from the day of administration	The percentage of subjects who died from any cause during the study.
Changes of the oxygen saturation.	3 months from the day of administration	Changes from baseline of the oxygen saturation.
The number of days of intubation, or where ventilator or oxygen therapy.	3 months from the day of administration	The number of days of intubation, or where ventilator or oxygen therapy.
Changes of chest x-ray findings in participants before and after administration.	3 months from the day of administration	Changes from baseline to 3 months of chest x-ray findings in participants before and after administration.
Comparison of the incidence and severity of preterm children's complications in participants before and after administration.	3 months from the day of administration	Comparison of the incidence and severity of preterm children's complications in participants before and after administration.

Trial Locations

Locations (1)

National Chen-Kung University Hospital; 🇨🇳 Tainan City, Taiwan